Johan F Paulsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/766546/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Design of a GLPâ€1/PYY Dual Acting Agonist. Angewandte Chemie - International Edition, 2021, 60, 8268-8275.	13.8	17
2	The Design of a GLPâ€1/PYY Dual Acting Agonist. Angewandte Chemie, 2021, 133, 8349-8356.	2.0	1
3	Rational Development of Stable PYY3–36 Peptide Y2 Receptor Agonists. Pharmaceutical Research, 2021, 38, 1369-1385.	3.5	5
4	The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs. Scientific Reports, 2021, 11, 21179.	3.3	13
5	Elucidation of the Binding Mode of the Carboxyterminal Region of Peptide YY to the Human Y ₂ Receptor. Molecular Pharmacology, 2018, 93, 323-334.	2.3	28
6	Design of Y ₂ Receptor Selective and Proteolytically Stable PYY _{3–36} Analogues. Journal of Medicinal Chemistry, 2018, 61, 10519-10530.	6.4	27
7	Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in <i>Caenorhabditis elegans</i> . Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7710-E7719.	7.1	23
8	InÂVivo Seeding and Cross-Seeding of Localized Amyloidosis. American Journal of Pathology, 2015, 185, 834-846.	3.8	235
9	High Plasma Levels of Islet Amyloid Polypeptide in Young with New-Onset of Type 1 Diabetes Mellitus. PLoS ONE, 2014, 9, e93053.	2.5	23
10	Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications. ACS Medicinal Chemistry Letters, 2013, 4, 1228-1232.	2.8	6
11	A Parallel Semisynthetic Approach for Structure–Activity Relationship Studies of Peptideâ€YY. ChemMedChem, 2013, 8, 1505-1513.	3.2	7
12	Improving membrane binding as a design strategy for amphipathic peptide hormones: 2â€helix variants of PYY3â€36. Journal of Peptide Science, 2012, 18, 579-587.	1.4	7
13	Ferret islet amyloid polypeptide (IAPP): characterization of <i>in vitro</i> and <i>in vivo</i> amyloidogenicity. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 222-228.	3.0	9
14	Extraneural manifestations of prion infection in GPI-anchorless transgenic mice. Virology, 2011, 411, 1-8.	2.4	8
15	Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies. Experimental Neurology, 2010, 221, 267-274.	4.1	106
16	Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. Acta Diabetologica, 2009, 46, 35-42.	2.5	4
17	Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18563-18568.	7.1	76
18	Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice. Cell, 2009, 139, 1157-1169.	28.9	450

Johan F Paulsson

#	Article	IF	CITATIONS
19	Amyloid Deposition in Transplanted Human Pancreatic Islets: A Conceivable Cause of Their Long-Term Failure. Experimental Diabetes Research, 2008, 2008, 1-8.	3.8	33
20	Real-Time Monitoring of Apoptosis by Caspase-3-Like Protease Induced FRET Reduction Triggered by Amyloid Aggregation. Experimental Diabetes Research, 2008, 2008, 1-12.	3.8	16
21	Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets. Diabetologia, 2006, 49, 1237-1246.	6.3	105
22	Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes. Diabetologia, 2006, 50, 195-201.	6.3	20
23	Aberrant Processing of Human Proislet Amyloid Polypeptide Results in Increased Amyloid Formation. Diabetes, 2005, 54, 2117-2125.	0.6	109